发布求助
文献互助 智能选刊 最新文献

Australian Prescriber最新文献

筛选
英文 中文
Pharmacological management of attention deficit hyperactivity disorder in adults. 成人注意缺陷多动障碍的药物治疗。
IF 4.2
Australian Prescriber Pub Date : 2026-02-01 DOI: 10.18773/austprescr.2026.002
Shuichi Suetani, Jaimie Hull, James G Scott
{"title":"Pharmacological management of attention deficit hyperactivity disorder in adults.","authors":"Shuichi Suetani, Jaimie Hull, James G Scott","doi":"10.18773/austprescr.2026.002","DOIUrl":"10.18773/austprescr.2026.002","url":null,"abstract":"<p><p>Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder that is characterised by inattention, hyperactivity or impulsivity. It affects around 3 to 5% of adults. The main pharmacotherapies for adults with ADHD include psychostimulants, such as methylphenidate and amphetamines (dexamfetamine and lisdexamfetamine), and non-psychostimulants such as atomoxetine. In Australia, the eligibility for subsidy under the Pharmaceutical Benefits Scheme varies depending on whether the patient was diagnosed with ADHD during childhood or adulthood. Individuals prescribed ADHD drugs should be monitored for both physical (e.g. cardiac symptoms, appetite changes, seizures) and psychiatric (e.g. mood disturbances, anxiety, psychosis) adverse effects. While pharmacological treatment is effective for adults with ADHD, it should be integrated into a broader, multidisciplinary approach that also includes nonpharmacological strategies such as psychological therapies and allied health support.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"49 1","pages":"10-15"},"PeriodicalIF":4.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12928839/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147286406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Defining psychotropic medicines in aged and disability care. 定义老年和残疾护理中的精神药物。
IF 4.2
Australian Prescriber Pub Date : 2026-02-01 DOI: 10.18773/austprescr.2026.007
Juanita Breen, Mandy Callary, Loren deVries
{"title":"Defining psychotropic medicines in aged and disability care.","authors":"Juanita Breen, Mandy Callary, Loren deVries","doi":"10.18773/austprescr.2026.007","DOIUrl":"https://doi.org/10.18773/austprescr.2026.007","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"49 1","pages":"2-3"},"PeriodicalIF":4.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12928836/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147286362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Secondary prevention of acute coronary syndromes: a summary of the new 2025 Australian guideline. 急性冠状动脉综合征的二级预防：新2025澳大利亚指南摘要
IF 4.2
Australian Prescriber Pub Date : 2026-02-01 DOI: 10.18773/austprescr.2026.008
Jasmine Just, David Brieger, Alexandra Bennett, Tom Briffa
{"title":"Secondary prevention of acute coronary syndromes: a summary of the new 2025 Australian guideline.","authors":"Jasmine Just, David Brieger, Alexandra Bennett, Tom Briffa","doi":"10.18773/austprescr.2026.008","DOIUrl":"https://doi.org/10.18773/austprescr.2026.008","url":null,"abstract":"<p><p>Acute coronary syndromes (ACS) remain a significant cause of disability and death in Australia. Following an initial acute coronary event, there is a significant risk of recurrence, particularly in the first 90 days. In April 2025, the National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand launched a new Australian clinical guideline for diagnosing and managing ACS. The guideline includes recommendations for the secondary prevention of ACS. Pharmacotherapies for secondary prevention of ACS include antiplatelet and anticoagulant drugs, lipid-modifying therapy, beta blockers and renin-angiotensin antagonist therapies, plus - in select groups - colchicine and other therapies. Vaccination against influenza and other respiratory pathogens is recommended. Nonpharmacological interventions include cardiac rehabilitation, healthy behaviour changes and screening for mental health conditions. The importance of providing strategies to support adherence to long-term therapies is also emphasised.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"49 1","pages":"30-35"},"PeriodicalIF":4.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12928837/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147286335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intra-articular hyaluronic acid (viscosupplementation) for osteoarthritis: is it effective? 关节内透明质酸（粘胶补充）治疗骨关节炎有效吗？
IF 4.2
Australian Prescriber Pub Date : 2026-02-01 DOI: 10.18773/austprescr.2026.005
Huai Leng Pisaniello, Shyan Goh, Rachelle Buchbinder
{"title":"Intra-articular hyaluronic acid (viscosupplementation) for osteoarthritis: is it effective?","authors":"Huai Leng Pisaniello, Shyan Goh, Rachelle Buchbinder","doi":"10.18773/austprescr.2026.005","DOIUrl":"https://doi.org/10.18773/austprescr.2026.005","url":null,"abstract":"<p><p>Viscosupplementation with intra-articular hyaluronic acid derivatives and cross-linked polymers of hyaluronic acid is increasingly used to treat symptomatic osteoarthritis in the knee, hip and other joints. Most guidelines conditionally recommend against its use to treat knee osteoarthritis, and strongly or conditionally recommend against its use for other joints, indicating a large evidence-to-practice gap. Conclusive evidence from randomised placebo-controlled trials indicates that intra-articular hyaluronic acid provides no important benefits for people with knee (and other joints) osteoarthritis, and may have potentially serious harms including septic arthritis and severe inflammatory joint and cutaneous reactions. Use of computed tomography scans to guide hyaluronic acid injection exposes the patient to unnecessary radiation and has an unwarranted financial and environmental cost. When the topic arises in clinical practice, prescribers should use a shared decision-making approach that includes an explanation as to why hyaluronic acid injection is not recommended care for osteoarthritis and offer alternatives, taking into consideration the patient's values and preferences.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"49 1","pages":"16-21"},"PeriodicalIF":4.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12928838/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147286353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Supporting the appropriate use of psychotropic medicines in aged and disability care. 支持在老年人和残疾人护理中适当使用精神药物。
IF 4.2
Australian Prescriber Pub Date : 2026-02-01 DOI: 10.18773/austprescr.2026.006
Stephen Macfarlane, Julian N Trollor, Rebecca Koncz, Maria Sukkar, Carolyn Hullick
{"title":"Supporting the appropriate use of psychotropic medicines in aged and disability care.","authors":"Stephen Macfarlane, Julian N Trollor, Rebecca Koncz, Maria Sukkar, Carolyn Hullick","doi":"10.18773/austprescr.2026.006","DOIUrl":"https://doi.org/10.18773/austprescr.2026.006","url":null,"abstract":"<p><p>Royal Commissions into the aged-care and disability sectors revealed significant concerns about the inappropriate use of psychotropic medicines as chemical restraint in people with cognitive disability or impairment. In response, the Australian Commission on Safety and Quality in Health Care developed the Psychotropic Medicines in Cognitive Disability or Impairment Clinical Care Standard (the Standard), aiming to guide psychotropic use and ensure best practice in supporting people with cognitive disability or impairment. This article provides an overview of the Standard and its application in the aged-care and disability sectors. The Standard promotes person-centred care and prioritises thorough assessment, non-medication strategies, and the development of individual behaviour support plans before considering psychotropic medicines. It encourages healthcare services to have clear policies around psychotropic use, including the need for documentation of non-medication strategies trialled before such use, and for monitoring the effectiveness of any psychotropic medicine prescribed. Informed consent is a regulatory requirement before using psychotropic medicines as a form of restrictive practice. Clear treatment goals, clinical handover during transitions of care, and regular psychotropic review and deprescribing are emphasised in the Standard to minimise harm, particularly in cases of long-term use and psychotropic polypharmacy.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"49 1","pages":"4-9"},"PeriodicalIF":4.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12928841/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147286370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ivosidenib for cholangiocarcinoma and acute myeloid leukaemia. 伊沃西地尼治疗胆管癌和急性髓性白血病。
IF 4.2
Australian Prescriber Pub Date : 2026-02-01 DOI: 10.18773/austprescr.2026.004
{"title":"Ivosidenib for cholangiocarcinoma and acute myeloid leukaemia.","authors":"","doi":"10.18773/austprescr.2026.004","DOIUrl":"https://doi.org/10.18773/austprescr.2026.004","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"49 1","pages":"36-38"},"PeriodicalIF":4.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12928840/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147286381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Australian clinical guideline for deprescribing in older people. 澳大利亚老年人开处方临床指南。
IF 4.2
Australian Prescriber Pub Date : 2025-12-01 DOI: 10.18773/austprescr.2025.055
{"title":"Australian clinical guideline for deprescribing in older people.","authors":"","doi":"10.18773/austprescr.2025.055","DOIUrl":"https://doi.org/10.18773/austprescr.2025.055","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 6","pages":"211"},"PeriodicalIF":4.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12711346/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145783677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Top 10 drugs 2024-25. 2024- 2025年十大药物。
IF 4.2
Australian Prescriber Pub Date : 2025-12-01 DOI: 10.18773/austprescr.2025.057
{"title":"Top 10 drugs 2024-25.","authors":"","doi":"10.18773/austprescr.2025.057","DOIUrl":"https://doi.org/10.18773/austprescr.2025.057","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 6","pages":"210"},"PeriodicalIF":4.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12711347/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145783728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fenfluramine for seizures associated with Dravet syndrome and Lennox-Gastaut syndrome. 芬氟拉明治疗与Dravet综合征和lenox - gastaut综合征相关的癫痫发作。
IF 4.2
Australian Prescriber Pub Date : 2025-12-01 DOI: 10.18773/austprescr.2025.054
{"title":"Fenfluramine for seizures associated with Dravet syndrome and Lennox-Gastaut syndrome.","authors":"","doi":"10.18773/austprescr.2025.054","DOIUrl":"10.18773/austprescr.2025.054","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 6","pages":"214-215"},"PeriodicalIF":4.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12711345/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145783649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Near-fatal reaction associated with cotrimoxazole, metformin and kidney impairment. 与复方新诺明、二甲双胍和肾脏损害相关的近乎致命的反应。
IF 4.2
Australian Prescriber Pub Date : 2025-12-01 DOI: 10.18773/austprescr.2025.053
John Marley
{"title":"Near-fatal reaction associated with cotrimoxazole, metformin and kidney impairment.","authors":"John Marley","doi":"10.18773/austprescr.2025.053","DOIUrl":"10.18773/austprescr.2025.053","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 6","pages":"208-209"},"PeriodicalIF":4.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12711349/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145783697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信
小红书